We investigated the mucosal distribution and neutralization potency of rhesus recombinant versions of the HIV-specific, broadly neutralizing antibody b12 (RhB12) following intravenous administration ...
Primary immunodeficiency (PID) diseases occur in about 1 in every 1200 individuals and are associated with recurrent infections and several comorbidities that contribute to its substantial morbidity ...
BioRx, a specialty infusion services provider, has introduced a health outcomes reporting program that provides routine clinical feedback on the use of home immunoglobulin (IgG) therapy in ...
Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of ...
SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...
“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...
KYOTO, Japan — Subcutaneous (SC) immunoglobulin offers several benefits compared with intravenous (IV) infusion as maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback